Author: claimsbot

1. A slip style bobber for fishing comprising:
a hollow central housing constructed from a joining of a first mating half and a second mating half;
the first and the second mating halves being conically shaped and having a wide end and a narrow end, the narrow ends including a aperture, the wide ends adapted to be joined to create the hollow central housing;
a pair of printed circuit boards having a power source, a light source, and a switch;
a mounting member received within the hollow central housing, the mounting member having a central tubular cavity, a first lobe, and a second lobe opposite the first lobe, the lobes having a groove and a raised detent for securing the printed circuit boards;
a first slip tube received within the central tubular cavity, the first slip tube cylindrically shaped with a diameter and having a inner side, a outer side, a interior end, and a exterior end, the interior end having a pair of radial grooves extending along the diameter of the outer side, the exterior end extending from the interior of the housing to the exterior of the bobber through the aperture of the narrow end of the housing;
a pair of o-ring gaskets received within the radial grooves of the first slip tube;
a second slip tube received within the central tubular cavity coaxial to the first slip tube, the second slip tube identical to the first slip tube;
a pair of o-ring gaskets received within the radial grooves of the second slip tube; and
a central o-ring gasket restrained between the joint of the first mating member and the second mating member.
2. The slip style bobber as claimed in claim 1, wherein the first mating half includes a rib to be received in a notch of the first lobe and second lobe.
3. The slip style bobber as claimed in claim 1, wherein the light source is a light emitting diode.
4. The slip style bobber as claimed in claim 1, wherein the first mating half and the second mating half are different colors.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for adopting a bistable display medium, comprising:
evenly mixing DFLCs, incurable nanoparticles, curable nanoparticles, and a photo initiator to form a mixture;
applying an low frequency field to the mixture, wherein the voltage is large enough to let DFLCs vertically stand; and
exposing with UV light, and the curable nanoparticles are cured to form some nano chains,
wherein the curable nanoparticles and the incurable nanoparticles have a weight ratio of about 1090 to 6040, and
the DFLCs and the combination of the curable nanoparticles and the incurable nanoparticles have a weight ratio of about 982 to 937, and
the curable nanoparticles and the photo initiator have a weight ratio of about 99.50.5 to 955.
2. The method as claimed in claim 1, wherein the incurable nanoparticles have a diameter of 7 nm to 50 nm, and the incurable nanoparticles comprise titanium oxide, silicon oxide, aluminum oxide, iron oxide, or combinations thereof.
3. The method as claimed in claim 1, wherein the curable nanoparticles have a diameter of 7 nm to 50 nm, and the core of the curable nanoparticles comprises titanium oxide, silicon oxide, aluminum oxide, iron oxide, or combinations thereof, and the surface of the curable nanoparticles has an organic segment comprising a carbon-carbon double bond.
4. A bistable display material, comprising:
98 to 93 parts by weight of DFLCs; and
2 to 7 parts by weight of nano composition,
wherein the nano composition is composed of 10 to 60 parts by weight of a nano chain and 90 to 40 parts by weight of incurable nanoparticles.
5. The bistable display material as claimed in claim 4, wherein the incurable nanoparticles have a diameter of 7 nm to 50 nm, and the incurable nanoparticles comprise titanium oxide, silicon oxide, aluminum oxide, iron oxide, or combinations thereof.
6. The bistable display material as claimed in claim 4, wherein the nano chain is cured of curable nanoparticles and a photo initiator, and the curable nanoparticles and the photo initiator have a weight ratio of about 99.50.5 to 955.
7. The bistable display material as claimed in claim 6, wherein the curable nanoparticles have a core-shell structure having a diameter of 7 nm to 50 nm, the core comprises titanium oxide, silicon oxide, aluminum oxide, iron oxide, or combinations thereof, and the surface has an organic segment comprising a carbon-carbon double bond.
8. A bistable display device, comprising:
a liquid crystal layer disposed between two substrates;
wherein the liquid crystal layer comprises the bistable display material as claimed in claim 4.
9. The bistable display device as claimed in claim 8, wherein the substrates comprise glass, quartz, plastic, rubber, polyester, or polycarbonate.

What is claimed is:

1. A method of cooking food with a rotisserie oven, the oven including and a spit assembly that slides into the oven guided by two tracks, the tracks being able to locate the spit assembly in two different positions, comprising the steps of:
inserting the spit assembly into the rotisserie oven and locating the spit assembly at the first position in the tracks;
preparing the food while the spit assembly is in the first position; and
when finished preparing the food, guiding the spit assembly further into the oven to the second position.
2. A method of cooking food with a rotisserie oven and a spit assembly that slides into the oven guided by two tracks, the tracks being able to locate the spit assembly in three different positions, the spit assembly not rotating in the first position and rotating in the second and third positions, and the spit assembly being closest to a heating source in the third position, comprising the steps of:
inserting the spit assembly into the rotisserie oven and locating the spit assembly at the first of the three positions in the tracks;
preparing the food while the spit assembly is in the first position; and
when finished preparing the food, guiding the spit assembly further into the oven to the second position or to the third position.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1-15. (canceled)
16. A compound of Formula (Ip3):
or a pharmaceutically acceptable salt thereof; and
wherein:
G1 is (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, cyano or nitro;
n is 0, 1 or 2;
G2a is (C1-C4)alkyl, or (C1-C4)haloalkyl;
G2b is hydrogen, methyl or ethyl;
R1 is methyl or ethyl;
R2 is phenyl or fluorophenyl; and
R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
17-20. (canceled)
21. The compound of claim 16, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
22. The compound of claim 16, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
23. The compound of claim 16, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
24-34. (canceled)
35. A method of treating a subject with a disease associated with the activity or expression of 11\u03b2-HSD1, comprising the step of administering to the subject an effective amount of a compound of Formula (Ip3):
or a pharmaceutically acceptable salt thereof; and
wherein:
G1 is (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, cyano or nitro;
n is 0, 1 or 2;
G2a is (C1-C4)alkyl or (C1-C4)haloalkyl;
G2b is hydrogen, methyl or ethyl;
R1 is methyl or ethyl;
R2 is phenyl or fluorophenyl; and
R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
36. The method of claim 35, wherein the disease is diabetes.
37. The method of claim 36, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
38. The method of claim 36, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
39. The method of claim 36, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
40. A method of inhibiting 11\u03b2-HSD1 activity comprising the step of administering to a human in need of such treatment an effective amount of a compound of Formula (Ip3):
or a pharmaceutically acceptable salt thereof; wherein:
G1 is (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, cyano or nitro;
n is 0, 1 or 2;
G2a is (C1-C4)alkyl or (C1-C4)haloalkyl;
G2b is hydrogen, methyl or ethyl;
R1 is methyl or ethyl;
R2 is phenyl or fluorophenyl; and
R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
41. The method of claim 40, wherein the human is in need of treatment for diabetes.
42. The method of claim 41, wherein the compound the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
43. The method of claim 41, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
44. The method of claim 41, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
45. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and a compound of Formula (Ip3):
or a pharmaceutically acceptable salt thereof and
wherein:
G1 is (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, cyano or nitro;
n is 0, 1 or 2;
G2a is (C1-C4)alkyl or (C1-C4)haloalkyl;
G2b is hydrogen, methyl or ethyl;
R1 is methyl or ethyl;
R2 is phenyl or fluorophenyl; and
R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
46. The pharmaceutical composition of claim 45, wherein the compound the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
47. The pharmaceutical composition of claim 45, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
48. The pharmaceutical composition of claim 45, wherein the compound is of the following Formula:
or a pharmaceutically acceptable salt thereof.
49. The compound of claim 16 wherein n is 0.